Results of multicenter comparative study of safety and efficacy of the drugs Leucostim? and Neupogen? in the treatment and prophylaxis of neutropenia in children
The results of a multicenter randomized double-blind clinical trial with crossover design on evaluating the effectiveness of two preparations of recombinant human granulocyte colony-stimulating factor - Leykostim® and Neupogen® - for treatment and prevention of neutropenia associated with chemotherapy of malignant neoplasms in children are presented. The study included 40 children aged 2 months to 17 years (median - 9 years) with various malignant tumors and the presence of indications for chemotherapy. It is shown that Leykostim® and Neupogen® administrations at the dose of 5 mg/kg/day in children are highly effective for treatment and prevention of neutropenia associated with chemotherapy of malignant neoplasms in all age’s children. Drug Leykostim ® on efficacy and safety was equal to drug Neupogen ® and was well tolerated.

Keywords: filgrastim, granulocyte colony-stimulating factor, chemotherapy of malignant tumors, neutropenia, children